What is Zacks Research’s Forecast for GSK FY2025 Earnings?

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for GSK in a research report issued to clients and investors on Wednesday, October 16th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $4.45 for the year, down from their previous forecast of $4.51. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.96 EPS, Q3 2026 earnings at $1.55 EPS and FY2026 earnings at $4.96 EPS.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion.

GSK has been the subject of several other reports. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Argus raised GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. Jefferies Financial Group upped their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $50.00.

GSK Stock Down 1.0 %

Shares of NYSE:GSK opened at $38.17 on Monday. The firm has a market cap of $79.10 billion, a PE ratio of 13.83, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a fifty day simple moving average of $41.40 and a 200 day simple moving average of $41.23. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. GSK has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were paid a $0.3843 dividend. This represents a $1.54 dividend on an annualized basis and a yield of 4.03%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On GSK

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. Wellington Management Group LLP grew its stake in shares of GSK by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 1,043,624 shares of the pharmaceutical company’s stock worth $38,677,000 after purchasing an additional 131,021 shares in the last quarter. &PARTNERS acquired a new position in GSK during the 1st quarter valued at about $299,000. AdvisorNet Financial Inc lifted its stake in shares of GSK by 1.6% in the 1st quarter. AdvisorNet Financial Inc now owns 21,053 shares of the pharmaceutical company’s stock worth $903,000 after acquiring an additional 324 shares during the period. Range Financial Group LLC boosted its holdings in shares of GSK by 11.3% in the first quarter. Range Financial Group LLC now owns 11,019 shares of the pharmaceutical company’s stock valued at $472,000 after acquiring an additional 1,117 shares in the last quarter. Finally, Gilman Hill Asset Management LLC increased its stake in shares of GSK by 5.2% during the first quarter. Gilman Hill Asset Management LLC now owns 57,452 shares of the pharmaceutical company’s stock valued at $2,463,000 after acquiring an additional 2,857 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.